303 related articles for article (PubMed ID: 27550344)
1. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
4. Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Ordóñez Mejia JL; Roberts MS; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4577-84. PubMed ID: 27185798
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.
Lopez ND; Phillips KM
Pharmacotherapy; 2014 Sep; 34(9):e162-8. PubMed ID: 25074285
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Gharibian KN; Mueller BA
Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.
Patel K; Roberts JA; Lipman J; Tett SE; Deldot ME; Kirkpatrick CM
Antimicrob Agents Chemother; 2011 Dec; 55(12):5868-73. PubMed ID: 21930888
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.
Economou CJP; Kielstein JT; Czock D; Xie J; Field J; Richards B; Tallott M; Visser A; Koenig C; Hafer C; Schmidt JJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2018 Aug; 52(2):151-157. PubMed ID: 29526606
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.
Sinnollareddy MG; Roberts MS; Lipman J; Lassig-Smith M; Starr T; Robertson T; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2016 Feb; 60(2):827-32. PubMed ID: 26596947
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti PG; Lugano M; Righi E; Della Rocca G; Bassetti M; Hope W; Pea F
Eur J Clin Pharmacol; 2018 Nov; 74(11):1449-1459. PubMed ID: 30032414
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients.
Aoyama T; Hirata K; Hirata R; Yamazaki H; Yamamoto Y; Hayashi H; Matsumoto Y
J Clin Pharm Ther; 2012 Jun; 37(3):356-63. PubMed ID: 21883330
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
18. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
Grau S; Luque S; Campillo N; Samsó E; Rodríguez U; García-Bernedo CA; Salas E; Sharma R; Hope WW; Roberts JA
J Antimicrob Chemother; 2015 Oct; 70(10):2854-61. PubMed ID: 26180134
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
